Completed PHASE1 INTERVENTIONAL 2-arm NCT00685139

Fasting Bioavailability Study of Zonisamide Capsules

A Relative Bioavailability Study of 100 mg Zonisamide Capsules Under Fasting Conditions

Sponsor: Mutual Pharmaceutical Company, Inc.

Conditions Healthy

Interventions Zonisamide (Zonegran®) 100 mg Capsule Zonisamide 100 mg Capsule

Updated 8 times since 2017 Last updated: Jan 11, 2010 Started: Jan 31, 2005 Primary completion: Mar 31, 2005 Completion: Mar 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00685139, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Mutual Pharmaceutical Company, Inc., it has been updated 8 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mutual Pharmaceutical Company, Inc.

Data source: Mutual Pharmaceutical Company, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.